IRAK4: potential therapeutic target for airway disease exacerbations.

Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.